How does the presence of indeterminate lymphadenopathy on PSMA PET scan alter your management of unfavorable intermediate risk prostate cancer?  

Some pelvic nodes have moderate SUV around 6. How do clinicopathologic factors such as PSA level and percentage of positive TRUS biopsy cores impact your approach? What if the lymph nodes appeared more suspicious with higher SUV?